Evidence map›Paper›PMID 38939041›Full record

ArticleResearch (Washington, D.C.)2024

Integrating Single-Cell and Spatial Transcriptomics to Uncover and Elucidate GP73-Mediated Pro-Angiogenic Regulatory Networks in Hepatocellular Carcinoma.

Jiazhou Ye, Xing Gao, Xi Huang, Shilin Huang, Dandan Zeng, Wenfeng Luo, Can Zeng, Cheng Lu, Lu Lu, Hongyang Huang and 12 more

Abstract read
In one paragraph

Article in Research (Washington, D.C.), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 49 papers.

0numbers the graph read from it
0cells of the map it votes in
49citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

49 citing papers in PubMed.

  1. Review
  2. Article
  3. Review
  4. Review
  5. Article
  6. Review
  7. Review
  8. Review
  9. Article
  10. Article
  11. Protein Lactylation in Liver Disease: A Comprehensive Review.Expert reviews in molecular medicine · 2026
    Review
  12. Review
  13. Review
  14. Article
  15. Review
  16. Article
  17. Article
  18. Review
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

22 authors.

Jiazhou YeDepartment of Hepatobiliary Surgery, Guangxi Medical University Cancer Hospital, Nanning 530021, China.
Xing GaoGuangxi Liver Cancer Diagnosis and Treatment Project Technology Research Center, Nanning 530021, China.
Xi HuangGuangxi Liver Cancer Diagnosis and Treatment Project Technology Research Center, Nanning 530021, China.
Shilin HuangGuangxi Liver Cancer Diagnosis and Treatment Project Technology Research Center, Nanning 530021, China.
Dandan ZengGuangxi Liver Cancer Diagnosis and Treatment Project Technology Research Center, Nanning 530021, China.
Wenfeng LuoGuangxi Liver Cancer Diagnosis and Treatment Project Technology Research Center, Nanning 530021, China.
Can ZengDepartment of Hepatobiliary Surgery, Guangxi Medical University Cancer Hospital, Nanning 530021, China.
Cheng LuDepartment of Hepatobiliary Surgery, Guangxi Medical University Cancer Hospital, Nanning 530021, China.
Lu LuGuangxi Liver Cancer Diagnosis and Treatment Project Technology Research Center, Nanning 530021, China.
Hongyang HuangDepartment of Hepatobiliary Surgery, Guangxi Medical University Cancer Hospital, Nanning 530021, China.
Kaixiang MoDepartment of Hepatobiliary Surgery, Guangxi Medical University Cancer Hospital, Nanning 530021, China.
Julu HuangDepartment of Hepatobiliary Surgery, Guangxi Medical University Cancer Hospital, Nanning 530021, China.
Shizhou LiDepartment of Hepatobiliary Surgery, Guangxi Medical University Cancer Hospital, Nanning 530021, China.
Minchao TangDepartment of Hepatobiliary Surgery, Guangxi Medical University Cancer Hospital, Nanning 530021, China.
Tianzhun WuGuangxi Liver Cancer Diagnosis and Treatment Project Technology Research Center, Nanning 530021, China.
Rongyun MaiDepartment of Hepatobiliary Surgery, Guangxi Medical University Cancer Hospital, Nanning 530021, China.
Min LuoGuangxi Liver Cancer Diagnosis and Treatment Project Technology Research Center, Nanning 530021, China.
Mingzhi XieGuangxi Liver Cancer Diagnosis and Treatment Project Technology Research Center, Nanning 530021, China.
Shan WangGuangxi Liver Cancer Diagnosis and Treatment Project Technology Research Center, Nanning 530021, China.
Yongqiang LiGuangxi Liver Cancer Diagnosis and Treatment Project Technology Research Center, Nanning 530021, China.
Yan LinGuangxi Liver Cancer Diagnosis and Treatment Project Technology Research Center, Nanning 530021, China.
Rong LiangGuangxi Liver Cancer Diagnosis and Treatment Project Technology Research Center, Nanning 530021, China.ORCID https://orcid.org/0000-0003-0343-3277

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Hepatocellular carcinoma (HCC) was characterized as being hypervascular. In the present study, we generated a single-cell spatial transcriptomic landscape of the vasculogenic etiology of HCC and illustrated overexpressed Golgi phosphoprotein 73 (GP73) HCC cells exerting cellular communication with vascular endothelial cells with high pro-angiogenesis potential via multiple receptor-ligand interactions in the process of tumor vascular development. Specifically, we uncovered an interactive GP73-mediated regulatory network coordinated with c-Myc, lactate, Janus kinase 2/signal transducer and activator of transcription 3 (JAK2/STAT3) pathway, and endoplasmic reticulum stress (ERS) signals in HCC cells and elucidated its pro-angiogenic roles in vitro and in vivo. Mechanistically, we found that GP73, the pivotal hub gene, was activated by histone lactylation and c-Myc, which stimulated the phosphorylation of downstream STAT3 by directly binding STAT3 and simultaneously enhancing glucose-regulated protein 78 (GRP78)-induced ERS. STAT3 potentiates GP73-mediated pro-angiogenic functions. Clinically, serum GP73 levels were positively correlated with HCC response to anti-angiogenic regimens and were essential for a prognostic nomogram showing good predictive performance for determining 6-month and 1-year survival in patients with HCC treated with anti-angiogenic therapy. Taken together, the aforementioned data characterized the pro-angiogenic roles and mechanisms of a GP73-mediated network and proved that GP73 is a crucial tumor angiogenesis niche gene with favorable anti-angiogenic potential in the treatment of HCC.

Identifiers

PMID38939041
PMCPMC11208919

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.